McKnight’s Senior Living October 31, 2023
(HealthDay News) — The US Food and Drug Administration is reviewing an application for the at-home use of a nasal spray flu vaccine called FluMist from AstraZeneca. The nasal spray has been on the market since 2003, but AstraZeneca is now asking the FDA to allow adults aged 18 to 49 years to be able to give themselves the vaccine or give it to children aged 2 through 17 years.
The FDA is slated to make a decision during the first few months of 2024, Lisa Glasser, head of US Medical Affairs Vaccines-Infectious Disease at AstraZeneca, told HealthDay. If approved, FluMist is expected to be available for self-administration for the 2024/2025 flu season. “Self-administration of FluMist could increase access to...
Today's Sponsors
Today's Sponsor